Trial NCT03597022

View at ClinicalTrials.gov 
Org. Study IDs: 19580
Secondary IDs: 2017-003324-67

Last trial update was posted on 2020-11-30

MeSH Interventions

Immunoglobulin G Immunoglobulins Lipoprotein-associated coagulation inhibitor

MeSH Conditions

Hemophilia A

Other Conditions

Hemophilia A and B

Stopping Reasons

Due to thrombosis

Limitations And Caveats

Acceptable safety and tolerability of befovacimab was not demonstrated in the study, prompting early termination of the study. The "post-hoc" SAP was used for analyses. The other SAP was pre-specified but became not applicable after the termination.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID